A double-blind, placebo controlled, randomized, two-stage, parallel-group, adaptive design phase 2a study to evaluate the effects of BMS-813160 in subjects with type 2 diabetes mellitus and diabetic kidney disease (DKD) who have residual macroalbuminuria despite treatment with an inhibitor of the renin-angiotensin system
Project: Types of projects › Project